Skip to content

News

Organization Information

1 DNA Way
South San Francisco CA 94080-4918
Phone: (650) 225-1000
Fax: (650) 225-6000

www.gene.com/gene/index.jsp

Ownership: Public
Stock Symbol: DNA
Revenue: $5.2 Billion

Our Leadership

  • Arthur D. Levinson, Ph.D., President and CEO
  • David Ebersman, Senior VP & CFO
  • Evan Morris, Vice President, Government Affairs
  • Sean Johnston, Senior Vice President, General Counsel
  • Joseph McCracken, VP, Business Development
  • Walter Moore, VP, Govt Affairs
  • John Whiting, VP, Controller and Chief Accouting Officer
  • Amy Gartner, Senior Director, Corporate Relations
  • Ramesh Kamath, Senior Director, Facility Engineering
  • Todd Kaufman, Director, State Government Affairs
  • Eric Olson, Director, Product Development Projects
  • Andrea Jackson, Associate Director, State Government Affairs
  • Mary O'Donovan, Senior Regulatory Scientist
  • Caroline Pecquet, Associate Director, Corporate Communications, Corporate Relations
  • Peter Muller, Director, Government Affairs
  • Geoffrey P. Teeter, Director, Corporate Relations
  • Geraldine O’Connor, Associate Director, Local Government Affairs
  • Shannon Steward, Executive Assistant
  • Glenn Brame, VP, Quality
  • Kristin Olson, Public Affairs & Advocacy Relations
  • David Burt, Associate Director, Government Affairs
  • Michael Doherty, Vice President, Global Head, Pharma Development Regulatory
  • Katherine Martin, Director, Government Affairs
  • Robin Snyder, Ph.D., Senior Communications Counselor, Corporate Relations
Founded: 1976
Region: Bay Area
CA Employees: 3700
Total Employees: 6226
Organization Type: Biotech

Genentech, Inc.

Organization Profile

Research at Genentech, the nation’s first biotechnology company, has led to 14 of the biotechnology-based products on the market today. Genentech markets 10 products in the United States. Genetech's current marketed products are: HERCEPTIN, a treatment for metastatic cancer; RITUXAN, a treatment for non-Hodgkin's lymphoma; TNKase, a new single-bolus thrombolytic (or "clot buster") for the treatment of acute myocardial infarction (or heart attack); ACTIVASE, a clot buster for the treatment of heart attack, acute ischemic stroke and pulmonary embolism; NUTROPIN DEPOT, the first long-acting dosage form of recombinant growth hormone for pediatric growth hormone deficiency (GHD); NUTROPIN, NUTROPIN AQ and NUTROPIN PEN, treatments for children with growth failure due to inadequate growth hormone secretion, for children with growth failure associated with chronic renal insufficency up to the time of renal transplantation, for the long-term treatment of short stature associated with Turner syndrome and for the treatment of GHD in adults; PROTROPIN for treating children with growth failure due to inadequate growth hormone secretion; PULMOZYME, the first new therapeutic approach for cystic fibrosis in 30 years. Research at Genentech focuses on three therapeutic areas as of medicine: oncology, cardiovascular disease and an opportunistic area. Potential products currently under investigation by Genentech scientists include a new therapy for asthma and allergic rhinitis, a possible treatment for psoriasis and potential cancer and cardiovascular treatments.

Disease Focus

Allergies (misc) , Breast Cancer , Cancer (misc) , Cardiovascular Disorder (misc) , Cystic fibrosis , Non-hodgkin's lymphoma , Respiratory tract infections , Stroke